hotspot
ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
advertisement
Arch declined to comment on the new fundraising.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
WuXi out of biotech trade group, U.S. and China relations to blame
Next article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： As demand for Covid shots wanes, Moderna seeks its next success
